TNFRSF9 and neoplasm: The injection dose of an anti‐4‐1BB antibody was chosen based on the finding of a prior study that demonstrated its treatment efficacy in the E. G7 tumor‐implanted C57BL/6 mouse model.[26] Treatment of the tumor‐bearing mice with anti–4‐1BB or TST alone resulted in 38% and 48% inhibition of tumor growth, respectively, compared to that in the control group (Figure 8B).